KRAS and colorectal carcinoma: Furthermore, compared to wild-type KRAS, mutated KRAS is rarely associated with MSI in CRC patients, whereas BRAF mutations, which occur in about 4–20% of CRCs, are linked to MSI in colorectal tumorigenesis [12].